By Deena Beasley
(Reuters) – Eli Lilly’s mid-stage trial of its next-generation “triple g” obesity drug candidate found that the highest dose of the weekly injection to led to weight loss of 24.2% after 48 weeks, the New England Journal of Medicine said on its website on Monday.
The drug, retatrutide, is part of a class known as incretins designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow stomach emptying and decrease appetite.
(Reporting By Deena Beasley, editing by Deepa Babington)
